Kiora and Théa Open Innovation Enter Partnership to Develop and Commercialize KIO-301
Read more
Contact MENU

News

06.30.16

EyeGate Announces Completion of $3.77 Million Registered Direct Offering

WALTHAM, Mass., June 30, 2016 -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for...
Read more
06.27.16

EyeGate Announces $3.77 Million Registered Direct Offering

WALTHAM, Mass., June 27, 2016 -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for...
Read more
06.01.16

EyeGate Announces Encouraging Interim Data from Phase 1b/2a Clinical Trial of EGP-437 for Treatment of Ocular Inflammation and Pain Post Cataract Surgery

WALTHAM, Mass., June 01, 2016 -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for...
Read more
05.24.16

EyeGate Pharma Announces At The Market Issuance Program

WALTHAM, Mass., May 24, 2016 -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (the “Company”) announced today that it has entered into an At The Market Issuance ("ATM") Sales Agreement, dated May 24, 2016,...
Read more
05.13.16

Eyegate Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Business Update

WALTHAM, Mass., May 13, 2016 -- Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for...
Read more
05.06.16

EyeGate Pharma Appoints Dr. Brenda K. Mann as Vice President, Research and Development

WALTHAM, Mass., May 06, 2016 -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems...
Read more
04.27.16

EyeGate Pharma Appoints Ryan R. Brenneman as Chief Financial Officer

WALTHAM, Mass., April 27, 2016 -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for...
Read more
04.26.16

EyeGate Pharma to Present Four Posters at ARVO 2016 Annual Meeting Supporting Development of CMHA-S

WALTHAM, Mass., April 26, 2016 -- Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for...
Read more